New insight into systemic mastocytosis mediated by cytokines IL-1β and IL-33: Potential inhibitory effect of IL-37.
IL-1
IL-33
IL-37
Inflammation
Mast cells
Mastocytosis
Journal
European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354
Informations de publication
Date de publication:
05 Sep 2019
05 Sep 2019
Historique:
received:
15
02
2019
revised:
18
06
2019
accepted:
18
06
2019
pubmed:
23
6
2019
medline:
22
1
2020
entrez:
23
6
2019
Statut:
ppublish
Résumé
Systemic mastocytosis in various forms is characterized by mast cell (MC) infiltration of the bone marrow and other internal organs. The most common form is the indolent one with life expectancy similar to the normal population, while the systemic aggressive myeloproliferative type presents serious damage to various organs and is associated with mature and immature atypical mast cells. In systemic mastocytosis patients, MCs could be activated with consequent severe anaphylactic reactions, along with other symptoms. MCs, which are reactive to a variety of external factors such as allergens or other inflammatory or physical stimuli, derive from pluripotent cellular progenitor CD34
Identifiants
pubmed: 31228452
pii: S0014-2999(19)30425-X
doi: 10.1016/j.ejphar.2019.172473
pii:
doi:
Substances chimiques
IL37 protein, human
0
Interleukin-1
0
Interleukin-1beta
0
Interleukin-33
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
172473Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.